Business
Amgen Stock: Biotech Giant Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
Amgen (AMGN) stock popped Wednesday on what one analyst called an “impressive” quarter featuring double-digit growth for nearly two dozen of its products. The best growth came from Uplizna, a treatment for several rare autoimmune conditions. Sales nearly doubled, rocketing 90% to $335 million. Meanwhile, revenue from the company’s biggest moneymaker, cholesterol drug Repatha, surged 37% to $953 million. Both…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login